ATE308609T1 - Pth rezeptor und testverfahren unter verwendung desselben - Google Patents

Pth rezeptor und testverfahren unter verwendung desselben

Info

Publication number
ATE308609T1
ATE308609T1 AT98965037T AT98965037T ATE308609T1 AT E308609 T1 ATE308609 T1 AT E308609T1 AT 98965037 T AT98965037 T AT 98965037T AT 98965037 T AT98965037 T AT 98965037T AT E308609 T1 ATE308609 T1 AT E308609T1
Authority
AT
Austria
Prior art keywords
receptor
same
pth receptor
testing method
ligand binding
Prior art date
Application number
AT98965037T
Other languages
English (en)
Inventor
Thomas J Gardella
Henry M Kronenberg
John T Potts Jr
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE308609T1 publication Critical patent/ATE308609T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72Receptors; Cell surface antigens; Cell surface determinants for hormones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT98965037T 1998-12-31 1998-12-31 Pth rezeptor und testverfahren unter verwendung desselben ATE308609T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/027862 WO2000040698A1 (en) 1998-12-31 1998-12-31 Pth receptor and screening assay utilizing the same

Publications (1)

Publication Number Publication Date
ATE308609T1 true ATE308609T1 (de) 2005-11-15

Family

ID=22268582

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98965037T ATE308609T1 (de) 1998-12-31 1998-12-31 Pth rezeptor und testverfahren unter verwendung desselben

Country Status (9)

Country Link
US (2) US7169567B1 (de)
EP (2) EP1612263A1 (de)
JP (1) JP2002534081A (de)
AT (1) ATE308609T1 (de)
AU (1) AU2023499A (de)
DE (1) DE69832206T2 (de)
DK (1) DK1141237T3 (de)
ES (1) ES2251793T3 (de)
WO (1) WO2000040698A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1447600A (en) * 1998-10-22 2000-05-08 Thomas J. Gardella Bioactive peptides and peptide derivatives of parathyroid hormone (pth) and parathyroid hormone-related peptide (pthrp)
DE69942035D1 (de) 1998-11-25 2010-04-01 Gen Hospital Corp Menschliches parathyroidhormon, modifikationen, herstellung und verwendung
EP1612263A1 (de) 1998-12-31 2006-01-04 The General Hospital Corporation PTH Rezeptor und Testverfahren unter Verwendung desselben
WO2001023521A2 (en) * 1999-09-29 2001-04-05 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
US7572765B2 (en) 2001-07-23 2009-08-11 The General Hospital Corporation Conformationally constrained parathyroid hormone (PTH) analogs
AU2003220380A1 (en) * 2003-03-19 2004-11-19 Bristol-Myers Squibb Company CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH Alpha-HELIX STABILIZERS
JP4871128B2 (ja) * 2003-07-17 2012-02-08 ザ ジェネラル ホスピタル コーポレイション 高次構造的に制約された副甲状腺ホルモン(pth)アナログ
EP2054077A4 (de) * 2006-08-04 2010-10-13 Gen Hospital Corp Polypeptidderivate des parathyroidhormons (pth)
EP1961765A1 (de) * 2006-12-08 2008-08-27 Zealand Pharma A/S Verkürzte PTH-Peptide mit zyklischer Konformation
US20090023655A1 (en) * 2007-04-02 2009-01-22 Louis Luttrell Biased Ligands for Receptors Such as the PTH Receptor
BRPI0814962B8 (pt) 2007-08-01 2021-05-25 Chugai Pharmaceutical Co Ltd métodos in vitro para determinar se um composto candidato é um agonista de longa duração ou de curta duração de um receptor acoplado à proteína g, polipeptídeo, seu uso e composição farmacêutica
WO2009155283A2 (en) * 2008-06-17 2009-12-23 Duke University Radiolabled cyclopamine assay for the smoothened receptor
WO2010051473A2 (en) * 2008-10-31 2010-05-06 The Uab Research Foundation Identifying parathyroid hormone agonists and antagonists
US8563513B2 (en) 2009-03-27 2013-10-22 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
US9492508B2 (en) 2010-05-13 2016-11-15 The General Hospital Corporation Parathyroid hormone analogs and uses thereof
CN105986001B (zh) * 2015-02-12 2019-12-03 上海交通大学 一种基于膜结合蛋白和荧光互补的高通量猎物拮抗剂筛选方法
EP3765061A4 (de) 2018-03-16 2022-01-26 The General Hospital Corporation Parathormon-polypeptidkonjugate und verfahren zu deren verwendung

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
WO1987001130A1 (en) 1985-08-15 1987-02-26 Stauffer Chemical Company Tryptophan producing microorganism
US5217896A (en) 1988-12-30 1993-06-08 Oncogene Science, Inc. Monoclonal antibodies recognizing parathyroid hormone-like protein
WO1991005050A1 (en) 1989-09-29 1991-04-18 Her Majesty In Right Of Canada As Represented By The National Research Council Of Canada Synthesis of mature human parathyroid hormone
DE59109269D1 (de) 1990-06-28 2005-12-15 Hoechst Ag Fusionsproteine mit Immunglobulinanteilen, ihre Herstellung und Verwendung
US5462856A (en) 1990-07-19 1995-10-31 Bunsen Rush Laboratories, Inc. Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins
JPH0532696A (ja) 1990-09-28 1993-02-09 Takeda Chem Ind Ltd 副甲状腺ホルモン誘導体
WO1992017602A1 (en) 1991-04-05 1992-10-15 The General Hospital Corporation Office Of Technology Affairs Parathyroid hormone receptor and dna encoding same
US5434246A (en) 1992-03-19 1995-07-18 Takeda Chemical Industries, Ltd. Parathyroid hormone derivatives
US5814603A (en) 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
AU672790B2 (en) 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
CA2126132A1 (en) 1994-06-17 1995-12-18 Witold Neugebauer Peptide synthesis on chitosan
US5556940A (en) 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
CA2178894A1 (en) 1995-06-15 1996-12-16 Tsunehiko Fukuda Parathyroid hormone derivatives and their use
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
JP4122061B2 (ja) 1996-08-02 2008-07-23 ナショナル リサーチ カウンシル オブ カナダ 骨粗鬆症の治寮のための副甲状腺ホルモン類似体
EP1030658A1 (de) 1997-10-14 2000-08-30 Eli Lilly And Company Verfahren zum aufbau und zur erhaltung von knochen
AU1447600A (en) 1998-10-22 2000-05-08 Thomas J. Gardella Bioactive peptides and peptide derivatives of parathyroid hormone (pth) and parathyroid hormone-related peptide (pthrp)
WO2000031137A1 (en) 1998-11-25 2000-06-02 The General Hospital Corporation Amino-terminal modified parathyroid hormone (pth) analogs
DE69942035D1 (de) 1998-11-25 2010-04-01 Gen Hospital Corp Menschliches parathyroidhormon, modifikationen, herstellung und verwendung
AU4217299A (en) 1998-11-30 2000-06-19 General Hospital Corporation, The Pth1r and pth3r receptors, methods and uses thereof
EP1147133B1 (de) 1998-12-31 2008-08-06 The General Hospital Corporation Peptide, bestehend aus zwei funktionellen PTH-Domänen, die durch ein Linkermolekül verknüpft sind, und Derivate davon
EP1612263A1 (de) 1998-12-31 2006-01-04 The General Hospital Corporation PTH Rezeptor und Testverfahren unter Verwendung desselben
US7057012B1 (en) * 1998-12-31 2006-06-06 The General Hospital Corporation PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
US7022815B1 (en) * 1999-09-29 2006-04-04 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (PTH)
WO2001023521A2 (en) 1999-09-29 2001-04-05 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
ES2316354T3 (es) 1999-09-29 2009-04-16 The General Hospital Corporation Derivados polipeptidos de la hormona paratiroidea (pth).
US7572765B2 (en) 2001-07-23 2009-08-11 The General Hospital Corporation Conformationally constrained parathyroid hormone (PTH) analogs
US7521528B2 (en) 2003-01-24 2009-04-21 The General Hospital Corporation Conformationally constrained parathyroid hormone (PTH) analogs with lactam bridges
AU2003220380A1 (en) 2003-03-19 2004-11-19 Bristol-Myers Squibb Company CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH Alpha-HELIX STABILIZERS
JP4871128B2 (ja) 2003-07-17 2012-02-08 ザ ジェネラル ホスピタル コーポレイション 高次構造的に制約された副甲状腺ホルモン(pth)アナログ

Also Published As

Publication number Publication date
ES2251793T3 (es) 2006-05-01
EP1141237A4 (de) 2003-03-19
AU2023499A (en) 2000-07-24
JP2002534081A (ja) 2002-10-15
EP1141237A1 (de) 2001-10-10
US20070117969A1 (en) 2007-05-24
US7169567B1 (en) 2007-01-30
DE69832206T2 (de) 2006-08-03
EP1612263A1 (de) 2006-01-04
EP1141237B1 (de) 2005-11-02
WO2000040698A1 (en) 2000-07-13
DK1141237T3 (da) 2006-02-13
DE69832206D1 (de) 2005-12-08

Similar Documents

Publication Publication Date Title
ATE308609T1 (de) Pth rezeptor und testverfahren unter verwendung desselben
DE69822484D1 (de) Methoden zur bestimmung der rezeptoraktivität und dafür verwendbare konstrukte
DE69723860D1 (de) VERFAHREN ZUR BESTIMMUNG VON IgE
DE69227347D1 (de) Auf rezeptorgrundlage arbeitende screening-verfahren für amylin-agonisten und- antagonisten
ATE139784T1 (de) Hybrid-rezeptoren, diese kodierende nukleinsäure, ihre herstellung und ihre verwendung zur bestimmung von liganden sowie deren antagonisten oder agonisten
WO1998010068A3 (en) Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
WO2000021987A3 (en) A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease
ATE512233T1 (de) Screeningverfahren für die aktivität von agenzien unter verwendung von teleosten
DE69837473D1 (de) Verwendung von antagonisten der zentralen kannabinoidrezeptoren zur regulierung von suchterscheinungen
DE69738528D1 (de) Gemischte g-proteinzusammensetzung und ihre verwendung
ATE177535T1 (de) Identifizierung von liganden durch selektive vermehrung von, durch rezeptoren tranzfizierten zellen
ATE433106T1 (de) Bestimmungsmethode fur liganden der nuklearen rezeptoren
IL139163A (en) Method of predicting the ability of compounds to modulate the biological activity of receptors
DE69928250D1 (de) Analytisches verfahren unter verwendung von multipelviren-markierung
ATE142259T1 (de) Screening nach proteinpartnern und deren verwendung
DE69731964D1 (de) Map-kinase: polypeptide, polynukleotide und ihre verwendung
DE69535831D1 (de) Hemopoietin-rezeptor
ATE353364T1 (de) Transkriptions zwischen faktor-2 tif2
DE69825583D1 (de) Methode zum bestimmen der aktivierung von zytokinrezeptoren mit hilfe eines antikörpers
DE69837399D1 (de) Verfahren zum screening von tgf-beta inhibierenden substanzen
DE60129719D1 (de) Screening-verfahren zum identifizieren von g-proteinen und anderen verbindungen,die die phosphodiesterase (pde)-aktivität beeinflussen
DE69926624D1 (de) Verfahren zum screenen einer die oligomerisierung von rezeptorproteinmolekülen fördernden substanz
DE69702918D1 (de) Verfahren zum vorhersagen der verdaulichkeit von futtermaterialien
ES2085822B1 (es) Procedimiento para la caracterizacion de ligantes asfalticos mediante un ensayo de perdida por desgaste.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties